Bacterial infections:

Recent Updates:

Monograph added.

Indications for KIMYRSA:

Susceptible acute bacterial skin and skin structure infections (ABSSSI).

Adult Dosage:

Give by IV infusion over 1hr. ≥18yrs: 1200mg as a single dose.

Children Dosage:

<18yrs: not established.

KIMYRSA Contraindications:

Use of IV unfractionated heparin sodium for 120hrs (5 days) after oritavancin administration.

KIMYRSA Warnings/Precautions:

History of glycopeptide allergy. Discontinue immediately if acute hypersensitivity reaction occurs. Consider stopping or slowing infusion if infusion-related reactions occur. Evaluate if Clostridioides difficile-associated diarrhea is suspected or confirmed. Monitor for osteomyelitis; use alternative therapy if suspected or diagnosed. Severe hepatic or renal impairment: not studied. Pregnancy. Nursing mothers.

KIMYRSA Classification:

Lipoglycopeptide.

KIMYRSA Interactions:

Increased risk of bleeding with concomitant warfarin; may prolong aPTT for up to 120hrs, PT/INR for up to 12hrs, and ACT for up to 24hrs; monitor for bleeding. Avoid concomitant with drugs that are predominantly metabolized by one of the affected CYP450 enzymes. May increase concentrations of CYP2C9/CYP2C19 substrates. May decrease concentrations of CYP3A4/CYP2D6 substrates. May interfere with coagulation tests; consider non-phospholipid dependent test (eg, Factor Xa assay) or alternative anticoagulant not requiring aPTT monitoring.

Adverse Reactions:

Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea; infusion-related reactions.

Generic Drug Availability:

NO

How Supplied:

Single-dose vial—1

Pricing for KIMYRSA

1200mg vial (Qty: 1)
Appx. price $5978020
GoodRx